GO:0014063 negative regulation of serotonin secretion: Signaling Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0014063 (negative regulation of serotonin secretion) describes any process that stops, prevents, or reduces the regulated release of serotonin.
• Serotonin (5-hydroxytryptamine, 5-HT) secretion is controlled at multiple levels, including synthesis, vesicular packaging, transporter-mediated reuptake, and receptor feedback.
• The serotonin transporter SLC6A4 is a central negative regulator of extracellular serotonin and is a validated drug target in cancer and neuropsychiatric disease.
• Peripheral serotonin attenuation inhibits tumor growth and enhances immune checkpoint blockade therapy in murine models.
• Gut microbiota and their metabolites, such as lactic acid, can modulate tryptophan-to-serotonin conversion and thereby influence host physiology.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of genes that negatively regulate serotonin secretion.
Description
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter and hormone with essential roles in the central nervous system, gastrointestinal tract, and immune system. Its regulated release is tightly controlled because excessive or prolonged serotonin signaling contributes to multiple pathologies, including cancer progression, immune evasion, and neuropsychiatric disorders. The Gene Ontology term GO:0014063, negative regulation of serotonin secretion, captures the biological processes that stop, prevent, or reduce the frequency, rate, or extent of regulated serotonin release. Understanding this term is critical for researchers studying neurotransmitter homeostasis, tumor immunology, and gut-brain axis signaling. Mechanistically, negative regulation of serotonin secretion can occur through transporter-mediated reuptake, feedback inhibition of release machinery, receptor-mediated signaling, and metabolic control of serotonin synthesis. For example, the serotonin transporter SLC6A4 (SERT) clears extracellular serotonin and limits its availability, thereby acting as a negative regulator of serotonin secretion. In CD8+ T cells, a GAPDH serotonylation system couples glycolytic metabolism to antitumor immunity, illustrating how intracellular serotonin handling can shape immune responses. These findings highlight that negative regulation of serotonin secretion is not a single pathway but a network of molecular checkpoints. This article integrates authoritative QuickGO annotation for GO:0014063 with real PubMed literature to provide a research-grade overview of the genes, mechanisms, diseases, and experimental models relevant to negative regulation of serotonin secretion. It is intended for scientists designing CRISPR screens, knockout models, or pharmacological studies targeting serotonin release pathways.
negative regulation of serotonin secretion At A Glance
| GO ID | GO:0014063 |
|---|---|
| GO term | negative regulation of serotonin secretion |
| Ontology | biological_process |
| Definition | Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of serotonin. |
| Synonym | down regulation of serotonin secretion; down-regulation of serotonin secretion; downregulation of serotonin secretion; inhibition of serotonin secretion; positive regulation of serotonin release |
| Major function | Limits extracellular serotonin availability by reuptake, feedback inhibition, or metabolic control. |
| Related transporters | SLC6A4 (SERT) is a key negative regulator of serotonin secretion. |
| Related receptors | HTR2B and other serotonin receptors modulate downstream signaling and feedback. |
| Physiological context | Gut homeostasis, psychological stress, lactation, and antitumor immunity. |
What Is GO:0014063?
GO:0014063 (negative regulation of serotonin secretion) is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the regulated release of serotonin. It encompasses molecular events such as transporter-mediated reuptake, receptor feedback, and metabolic control that collectively dampen serotonin secretion.
Why Is negative regulation of serotonin secretion Important in Cell Biology?
Negative regulation of serotonin secretion is important because dysregulated serotonin release contributes to cancer progression, immune evasion, and neuropsychiatric disorders. Pharmacological or genetic attenuation of peripheral serotonin can inhibit tumor growth and enhance immune checkpoint blockade therapy, demonstrating the therapeutic potential of targeting this process. In the brain, serotonin dysregulation is associated with negative symptoms of schizophrenia, underscoring the clinical relevance of serotonin secretion control. Thus, understanding GO:0014063 provides a foundation for developing interventions that modulate serotonin availability in disease.
• Serotonin transporter SLC6A4 negatively regulates serotonin secretion and is a target in cancer immunotherapy.
• Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade in murine models.
• GAPDH serotonylation couples CD8+ T cell glycolytic metabolism to antitumor immunity, linking serotonin handling to immune function.
• Gut microbiota-derived lactic acid enhances tryptophan to 5-HT conversion, affecting anxiety-like behavior.
• Serotonin dysregulation is implicated in schizophrenia and negative symptoms.
• HTR2B regulates lipid metabolism and inhibits ferroptosis in gastric cancer, showing receptor-level control.
• Serotonin and serotonin transport regulate lactation, highlighting physiological roles beyond the brain.
• Negative regulation of serotonin secretion is relevant to gut homeostasis and psychological stress responses.
What Happens During negative regulation of serotonin secretion?
Transporter-mediated reuptake
In simple terms: Cells pull serotonin back inside to stop it from signaling too much.
The serotonin transporter SLC6A4 (SERT) is a primary negative regulator of serotonin secretion by clearing extracellular serotonin into cells. In tumors, SERT-mediated serotonin uptake limits the intratumoral serotonin axis and modulates antitumor immunity. This reuptake mechanism is a key node in GO:0014063 because it directly reduces the amount of serotonin available for regulated release.
Feedback inhibition via receptors
In simple terms: Serotonin receptors can send signals that tell cells to stop releasing more serotonin.
Serotonin receptors such as HTR2B can modulate downstream signaling and feedback that limits serotonin release. In gastric cancer, HTR2B regulates lipid metabolism and inhibits ferroptosis, illustrating how receptor-mediated signaling intersects with serotonin secretion control. Such receptor feedback loops contribute to the negative regulation defined by GO:0014063.
Metabolic control of serotonin synthesis
In simple terms: The raw materials and enzymes that make serotonin can be adjusted to reduce how much is available for release.
Gut-derived lactic acid enhances tryptophan to 5-hydroxytryptamine conversion via Akkermansia muciniphila, influencing anxiety-like behavior. This metabolic axis shows that microbial and metabolic inputs can modulate serotonin synthesis and, consequently, its secretion. Negative regulation of serotonin secretion therefore includes metabolic checkpoints that limit substrate availability.
Immune-metabolic coupling
In simple terms: Immune cells use serotonin internally in ways that affect their metabolism and function.
A GAPDH serotonylation system couples CD8+ T cell glycolytic metabolism to antitumor immunity, demonstrating that intracellular serotonin handling can shape immune responses. This coupling suggests that negative regulation of serotonin secretion may influence T cell function and tumor control. The interplay between serotonin metabolism and immunity is an emerging area within GO:0014063.
Physiological contexts of negative regulation
In simple terms: Serotonin release is controlled differently in the gut, brain, and mammary gland.
Serotonin and serotonin transport regulate lactation, indicating tissue-specific control of serotonin secretion. Gut homeostasis and psychological stress are also linked to serotonin signaling, where negative regulation helps maintain balance. These contexts highlight the broad physiological relevance of GO:0014063.
Key Genes Involved in GO:0014063 negative regulation of serotonin secretion
The following genes and proteins are experimentally implicated in negative regulation of serotonin secretion or closely related serotonin handling pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC6A4 | Serotonin transporter that clears extracellular serotonin | Central negative regulator of serotonin secretion; target in cancer immunotherapy |
| GAPDH | Glycolytic enzyme with serotonylation activity | Couples CD8+ T cell metabolism to antitumor immunity |
| HTR2B | Serotonin receptor 2B | Regulates lipid metabolism and ferroptosis in gastric cancer |
| TPH1 | Tryptophan hydroxylase 1 | Rate-limiting enzyme in peripheral serotonin synthesis |
| TPH2 | Tryptophan hydroxylase 2 | Rate-limiting enzyme in neuronal serotonin synthesis |
| AANAT | Aralkylamine N-acetyltransferase | Melatonin synthesis pathway linked to serotonin metabolism |
| MAO-A | Monoamine oxidase A | Degrades serotonin, limiting its availability |
| MAO-B | Monoamine oxidase B | Degrades serotonin and other monoamines |
| VMAT2 | Vesicular monoamine transporter 2 | Packages serotonin into vesicles for release |
| SERT | Serotonin transporter (protein product of SLC6A4) | Negative regulator of serotonin secretion |
| 5-HT1A | Serotonin receptor 1A | Feedback inhibition of serotonin release |
| 5-HT2A | Serotonin receptor 2A | Modulates downstream serotonin signaling |
| 5-HT2B | Serotonin receptor 2B (HTR2B) | Regulates lipid metabolism and ferroptosis |
| Akkermansia muciniphila | Gut microbe influencing tryptophan metabolism | Modulates serotonin conversion and anxiety |
| IL-2 | Cytokine linked to T cell immunity | Context for serotonin effects on antitumor immunity |
| PD-1 | Immune checkpoint receptor | Target of combination therapy with serotonin attenuation |
| PD-L1 | Immune checkpoint ligand | Modulated by serotonin axis in tumors |
How Is negative regulation of serotonin secretion Regulated?
Negative regulation of serotonin secretion is controlled by multiple layers, including transporter-mediated reuptake, receptor feedback, and metabolic inputs. SLC6A4 (SERT) directly limits extracellular serotonin and is a key node. HTR2B and other receptors provide feedback that can dampen release. Gut microbiota-derived metabolites such as lactic acid modulate tryptophan-to-serotonin conversion, adding a metabolic layer of control. In immune cells, GAPDH serotonylation links glycolytic metabolism to serotonin handling, suggesting that cellular metabolic state can influence serotonin secretion. These regulatory mechanisms collectively define the negative regulation captured by GO:0014063.
negative regulation of serotonin secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC6A4 | Cancer immunotherapy resistance | KO or overexpression in tumor cell lines and murine models |
| HTR2B | Gastric cancer and ferroptosis | KO or point-mutation in gastric cancer cell lines |
| TPH1 | Anxiety and gut-brain axis | KO or knock-in in murine models |
| GAPDH | Antitumor immunity | Point-mutation or knock-in in CD8+ T cells |
| MAO-A | Neuropsychiatric disorders | KO or overexpression in neuronal cell models |
Cancer and tumor immunity
Serotonin transporter SLC6A4 inhibits antitumor immunity by regulating the intratumoral serotonin axis, and attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine models. These findings position negative regulation of serotonin secretion as a therapeutic target in oncology.
Neuropsychiatric disorders
Serotonin dysregulation is associated with negative symptoms of schizophrenia, and serotonin transport mechanisms are implicated in mood and anxiety disorders. Gut-derived lactic acid enhances tryptophan to 5-HT conversion and regulates anxiety via Akkermansia muciniphila, linking gut-brain axis signaling to serotonin secretion control.
Gastrointestinal and metabolic disease
HTR2B regulates lipid metabolism and inhibits ferroptosis in gastric cancer, showing that serotonin receptor signaling intersects with metabolic disease pathways. Gut homeostasis and psychological stress are also connected through serotonin signaling, highlighting the broader physiological impact of GO:0014063.
Lactation and reproductive biology
Serotonin and serotonin transport regulate lactation, demonstrating that negative regulation of serotonin secretion has roles beyond the nervous system. This context is relevant for understanding mammary gland biology and reproductive physiology.
From negative regulation of serotonin secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC6A4 negatively regulate serotonin secretion in tumors? | SLC6A4 knockout in tumor cell lines and murine models |
| Does GAPDH serotonylation affect CD8+ T cell antitumor immunity? | GAPDH point-mutation or knock-in in CD8+ T cells |
| Does HTR2B modulate ferroptosis in gastric cancer? | HTR2B knockout or overexpression in gastric cancer cells |
| Does gut microbiota alter serotonin secretion? | Akkermansia muciniphila colonization in murine models |
| Does peripheral serotonin attenuation enhance checkpoint blockade? | Pharmacological or genetic serotonin attenuation in murine tumor models |
| Does serotonin transport regulate lactation? | SERT knockout or knock-in in mammary gland models |
How to Study the negative regulation of serotonin secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Test SLC6A4 or HTR2B as negative regulators |
| Point mutation | Specific amino acid function | Dissect GAPDH serotonylation |
| Knock-in | Tagged or mutant protein expression | Track SERT or HTR2B localization |
| Overexpression | Gain of function | Test sufficiency of negative regulation |
| Serotonin biosensors | Real-time serotonin release | Measure secretion dynamics |
| Metabolomics | Tryptophan and serotonin metabolites | Link gut microbiota to serotonin |
| Microbiome sequencing | Microbial composition | Identify Akkermansia muciniphila effects |
Genetic knockout and knockdown
CRISPR knockout of SLC6A4, HTR2B, or TPH1 can be used to test whether these genes negatively regulate serotonin secretion. Knockdown via RNAi provides complementary evidence for loss-of-function phenotypes.
Point-mutation and knock-in models
Point mutations in GAPDH can dissect serotonylation-dependent effects on T cell immunity. Knock-in of tagged SERT or HTR2B enables tracking of protein localization and function in serotonin secretion.
Overexpression and reporter assays
Overexpression of SLC6A4 or HTR2B can test sufficiency for negative regulation of serotonin secretion. Serotonin-sensitive reporters and biosensors allow real-time measurement of secretion dynamics.
Metabolic and microbiome profiling
Metabolomics and microbiome sequencing can identify microbial inputs such as Akkermansia muciniphila that modulate tryptophan-to-serotonin conversion. These methods link gut homeostasis to serotonin secretion control.
How CRISPR Can Be Used to Study GO:0014063 negative regulation of serotonin secretion
Knockout
CRISPR knockout of SLC6A4, HTR2B, or TPH1 can reveal whether these genes are required for negative regulation of serotonin secretion. Knockout models are essential for loss-of-function studies in cancer and neuropsychiatric disease.
Point Mutation
Point mutations in GAPDH can specifically disrupt serotonylation while preserving glycolytic activity, enabling precise dissection of serotonin-dependent immune regulation. Such models are valuable for separating enzymatic functions.
Knock-in
Knock-in of tagged SERT or HTR2B allows visualization and functional analysis of serotonin transport and receptor signaling in vivo. Tagged knock-in models facilitate proteomic and imaging studies.
Overexpression
Overexpression of SLC6A4 or HTR2B can test whether increased negative regulation of serotonin secretion alters tumor growth or immune responses. Overexpression models complement knockout studies.
How EDITGENE Supports negative regulation of serotonin secretion Research
Researchers studying negative regulation of serotonin secretion-related genes often need to determine whether a candidate gene is causally involved in limiting serotonin release, and CRISPR-based models provide the most direct way to test this. EDITGENE offers a suite of services to generate and characterize such models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of serotonin secretion research.
Frequently Asked Questions About negative regulation of serotonin secretion
What is GO:0014063?
GO:0014063 is the Gene Ontology term for negative regulation of serotonin secretion, defined as any process that stops, prevents, or reduces the regulated release of serotonin.
What genes are involved in negative regulation of serotonin secretion?
Key genes include SLC6A4 (SERT), HTR2B, GAPDH, TPH1, and MAO-A, which modulate serotonin reuptake, receptor feedback, and metabolism.
How does SLC6A4 negatively regulate serotonin secretion?
SLC6A4 encodes the serotonin transporter that clears extracellular serotonin, thereby limiting its availability for release.
What diseases are linked to negative regulation of serotonin secretion?
Cancer, schizophrenia, anxiety, and gastrointestinal disorders are linked to serotonin secretion dysregulation.
Can CRISPR be used to study serotonin secretion?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal studies of serotonin pathway genes.
What is the role of GAPDH in serotonin secretion?
GAPDH can undergo serotonylation, coupling CD8+ T cell glycolytic metabolism to antitumor immunity.
How does the gut microbiome affect serotonin secretion?
Gut microbes such as Akkermansia muciniphila can modulate tryptophan-to-serotonin conversion and influence anxiety-like behavior.
Does serotonin attenuation enhance cancer immunotherapy?
Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine models.
What receptors regulate serotonin release?
HTR2B and other serotonin receptors provide feedback that can dampen serotonin release.
What experimental models are used for serotonin secretion research?
Knockout, point-mutation, knock-in, and overexpression models in cell lines and mice are commonly used.
Conclusion
GO:0014063 (negative regulation of serotonin secretion) is a biologically and clinically important process that controls serotonin availability through transporters, receptors, and metabolic pathways. Its dysregulation is implicated in cancer, neuropsychiatric disorders, and gut-brain axis dysfunction. CRISPR-based models provide powerful tools to dissect the causal roles of genes such as SLC6A4, HTR2B, and GAPDH in this process. Continued research into negative regulation of serotonin secretion will likely yield new therapeutic strategies for serotonin-related diseases.
References
- 1. Li B et al.. 2025. Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis.. Cell 188(14):3823-3842.e21 PMID: 40403728
- 2. Wang X et al.. 2024. A GAPDH serotonylation system couples CD8(+) T cell glycolytic metabolism to antitumor immunity.. Mol Cell 84(4):760-775.e7 PMID: 38215751
- 3. Zhang H et al.. 2023. Understanding the Connection between Gut Homeostasis and Psychological Stress.. J Nutr 153(4):924-939 PMID: 36806451
- 4. Pan M et al.. 2025. Gut-derived lactic acid enhances tryptophan to 5-hydroxytryptamine in regulation of anxiety via Akkermansia muciniphila.. Gut Microbes 17(1):2447834 PMID: 39782002
- 5. Schneider MA et al.. 2021. Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models.. Sci Transl Med 13(611):eabc8188 PMID: 34524861
- 6. Osugo M et al.. 2026. Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative Symptoms.. JAMA Psychiatry 83(2):185-195 PMID: 41370075
- 7. Tu RH et al.. 2023. Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer.. Cancer Res 83(23):3868-3885 PMID: 38037454
- 8. Marshall AM et al.. 2014. Serotonin and serotonin transport in the regulation of lactation.. J Mammary Gland Biol Neoplasia 19(1):139-46 PMID: 24136337
